https://pipelinereview.com/enanta-pharmaceuticals-initiates-phase-1-clinical-study-of-edp-297-its-highly-potent-and-targeted-follow-on-farnesoid-x-receptor-agonist-for-the-treatment-of-non-alcoholic-steatohepatitis/